Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2
The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1
“The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which are supported by the highest quality scientific evidence.”
The foundation of Janssen’s scientific understanding in prostate cancer is based on the knowledge acquired through the development of innovative treatment options for mCRPC. Abiraterone acetate is an oral androgen biosynthesis inhibitor that is approved for the treatment of both mCRPC and metastatic hormone-sensitive prostate cancer, in Europe.3,4
“The addition of abiraterone acetate to the Essential Medicines List is a significant milestone for Janssen Oncology, reflecting the tireless efforts in recent years to bring optimal treatment options to patients with mCRPC,” said Biljana Naumovic, Vice President Commercial Strategy Lead Oncology for Europe, Middle East & Africa, Cilag GmbH International. “This direction from the WHO further emphasises that our work is not yet over. It is critical that patients with prostate cancer have access to treatments that their clinicians feel can benefit them and that we continue to support the prostate cancer community in our common goal of making cancer a manageable and potentially one day, a curable condition.”
# ENDS #
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com/emea. Follow us at www.twitter.com/janssenEMEA for our latest news. Janssen-Cilag S.A. and Cilag GmbH International are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
About abiraterone acetate (ZYTIGA®)
Abiraterone acetate plus prednisone/prednisolone is an approved therapy in mCRPC that inhibits production of androgens (which fuel prostate cancer growth) at all three sources that are important in prostate cancer - the testes, adrenals and the tumour itself.4,5,6
Abiraterone acetate is an oral therapy, taken in combination with prednisone/prednisolone for the treatment of:4
- newly diagnosed high risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)
- mCRPC in adult men who are asymptomatic or mildly symptomatic after failure of ADT in whom chemotherapy is not yet clinically indicated
- mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen
###
References
1 World Health Organisation. WHO updates global guidance on medicines and diagnostic tests to address health challenges, prioritize highly effective therapeutics, and improve affordable access. Available at https://www.who.int/news-room/detail/09-07-2019-who-updates-global-guidance-on-medicines-and-diagnostic-tests-to-address-health-challenges-prioritize-highly-effective-therapeutics-and-improve-affordable-access. Last accessed July 2019.
2 World Health Organisation. World Health Organization Model List of Essential Medicines. Available at: https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf?sequence=1&isAllowed=y. Last accessed July 2019.
3
Bedoya DJ and Mitsiades N (2012). Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. Expert Rev. Anticancer Ther. 12(1), 1–3.
4 European Medicines Agency. Zytiga Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/zytiga-epar-product-information_en.pdf. Last accessed July 2019.
5 Hoy, SM. et al. Abiraterone Acetate: A review of its use in patients with metastatic castration-resistant prostate cancer drugs. Drugs 2013; 73:2077-2091.
6 Ritch, CR. Cookson, MS. Advances in the management of castration resistant prostate cancer. BMJ. 2016 Oct 17;355:i4405. Doi: 10.1136/bmj.i4405.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190719005230/en/
Contact information
Media Enquiries:
Laura Coughlan
Phone: +353 87 147 9356
Investor Relations:
Christopher DelOrefice
Phone: +1 732 524 2955
Lesley Fishman
Phone: +1 732 524 3922
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DentalMonitoring Launches "Top Ortho Practice Award" to Recognize Data-Driven Excellence in Orthodontic Care20.6.2025 20:08:00 EEST | Press release
DentalMonitoring, the global leader in AI-powered remote monitoring for orthodontics, is proud to announce the launch of the Top Ortho Practice Award, the first-of-its-kind recognition program that celebrates top-performing orthodontic practices worldwide through objective, data-based analysis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250620540366/en/ Unlike traditional awards based on subjective nominations or popularity, the Top Ortho Practice Award is rooted in objective metrics derived from millions of patient scans and clinical interactions. Practices are selected based on exceptional outcomes in hygiene, compliance, and treatment effectiveness, using standardized benchmarks that reflect regional and global performance levels. The program identifies and celebrates practices that lead their territories in performance metrics derived from actual patient data, including hygiene, clinical techniques, and post-treatmen
SLB Announces Second-Quarter 2025 Results Conference Call20.6.2025 20:00:00 EEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 18, 2025 to discuss the results for the second quarter ending June 30, 2025. The conference call is scheduled to begin at 9:30 am U.S. Eastern time and a press release regarding the results will be issued at 7:00 am U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (833) 470-1428 within North America or +1 (404) 975-4839 outside of North America approximately 10 minutes prior to the start of the call and the access code is 719185. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/492107617 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 25, 2025, and can be accessed by dialing +1 (866) 813-9403 within North America or +1 (929)
TH Global Capital Named 'Boutique Investment Banking Firm of the Year' for the Third Year Running at the 16th Annual International M&A Awards20.6.2025 19:18:00 EEST | Press release
TH Global Capital, a global boutique investment banking firm with operations across 13 countries in the Americas, Europe, and Asia-Pacific, with a track record of closing transactions in 29 countries, has won four prestigious awards at the 16th Annual International M&A Awards, including ‘Boutique Investment Banking Firm of the Year’ for the third consecutive year. TH Global Capital’s awards include: Boutique Investment Banking Firm of the Year 2025 Corporate/Strategic Deal of the Year ($50MM-$100MM): For advising Cloobees, a Global Salesforce Summit Partner in Poland, on its strategic sale to New York headquartered Synechron. Regional Deal of the Year – Asia: For advising Brainvire, a leading global Digital Commerce and Digital Marketing agency in Asia, on its merger with Said Differently, a Falfurrias portfolio company in the US. M&A Deal of the Year ($50MM–$100MM): For advising Chamonix IT and Exposé, leading Australian companies in Digital Engineering and AI & Data Science respectiv
Kuwait Celebrates National Day at Expo 2025 Osaka with a Striking Showcase of Culture, Vision and Purpose20.6.2025 16:03:00 EEST | Press release
The State of Kuwait marked its National Day at Expo 2025 Osaka, Kansai, with a celebration that captivated audiences and strengthened the pavilion’s growing reputation as one of the most compelling destinations at the global event. The day’s activities brought together dignitaries, Expo visitors and international media in a vibrant tribute to Kuwait’s heritage, identity and forward-looking vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250620543251/en/ Kuwait celebrates National Day at Expo 2025 Osaka with a striking showcase of culture, vision and purpose (Photo: AETOSWire). The celebrations began with a parade featuring more than 100 participants, dressed in traditional attire and accompanied by music and movement. The procession drew large crowds across the Expo site, attracting attention for its energy, colour and cultural authenticity. The official ceremony took place at the National Day Hall within the Expo pre
HTEC Opened a New Office in Budapest, Signaling Further Expansion on the Hungarian Tech Scene20.6.2025 13:40:00 EEST | Press release
HTEC, a global AI-first company and a provider of technology design and engineering services, has opened a new office space in central Budapest, marking another step in the company’s strategic expansion across the Hungarian market. Located at Erzsébet krt. 2, the new space will serve as a hub for innovation and collaboration, welcoming new employees eager to shape the future of technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250620636346/en/ HTEC's Hungarian team at the opening of the company's new Budapest office HTEC partners with leading global companies to solve complex business problems in Financial Services, MedTech, Advanced Technologies, Retail, Telecommunications, and Enterprise Software & Platforms. Its end-to-end expertise—from product strategy to design and delivery—positions the company as a true extension of its clients’ teams. With a focus on strong partnerships and delivering measurable ROI fast, H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom